The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates

Acta Pol Pharm. 2006 Sep-Oct;63(5):450-2.

Authors

Maria Kraj¹, Ryszard Pogłód, Stanisław Maj, Katarzyna Owczarska

Affiliation

¹ Department of Haematology Institute of Haematology and Blood Transfusion, ul. Chocimska 5, Warszawa, Poland. mkraj@ihit.waw.pl

PMID: 17357613

No abstract available

Publication types

Case Reports

MeSH terms

Bone Density Conservation Agents / adverse effects*
Clodronic Acid / adverse effects
Diphosphonates / adverse effects*
Diphosphonates / therapeutic use
Humans
Imidazoles / adverse effects
Incidence
Jaw Diseases / chemically induced*
Male
Middle Aged
Multiple Myeloma / complications*
Multiple Myeloma / drug therapy
Osteonecrosis / chemically induced*
Pamidronate
Zoledronic Acid

Substances

Bone Density Conservation Agents
Diphosphonates
Imidazoles
Clodronic Acid
Zoledronic Acid
Pamidronate